CO2023013780A2 - Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4 - Google Patents

Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4

Info

Publication number
CO2023013780A2
CO2023013780A2 CONC2023/0013780A CO2023013780A CO2023013780A2 CO 2023013780 A2 CO2023013780 A2 CO 2023013780A2 CO 2023013780 A CO2023013780 A CO 2023013780A CO 2023013780 A2 CO2023013780 A2 CO 2023013780A2
Authority
CO
Colombia
Prior art keywords
inhibitor
combination
checkpoint inhibitor
ctla4 checkpoint
ctla4
Prior art date
Application number
CONC2023/0013780A
Other languages
English (en)
Spanish (es)
Inventor
Pietro Samuele Pozzi
Gianluca Fossati
Flavio Leoni
Elisabetta Galbiati
Christian Steinkuhler
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CO2023013780A2 publication Critical patent/CO2023013780A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2023/0013780A 2021-04-20 2023-10-19 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4 CO2023013780A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000009926A IT202100009926A1 (it) 2021-04-20 2021-04-20 Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4
PCT/EP2022/060287 WO2022223543A1 (en) 2021-04-20 2022-04-19 A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor

Publications (1)

Publication Number Publication Date
CO2023013780A2 true CO2023013780A2 (es) 2023-11-10

Family

ID=76808052

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0013780A CO2023013780A2 (es) 2021-04-20 2023-10-19 Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4

Country Status (17)

Country Link
US (1) US20240207228A1 (https=)
EP (1) EP4326259A1 (https=)
JP (1) JP2024515100A (https=)
KR (1) KR20230172001A (https=)
CN (1) CN117177745A (https=)
AR (1) AR125356A1 (https=)
AU (1) AU2022262199A1 (https=)
BR (1) BR112023021125A2 (https=)
CA (1) CA3213275A1 (https=)
CL (1) CL2023002894A1 (https=)
CO (1) CO2023013780A2 (https=)
IL (1) IL307649A (https=)
IT (1) IT202100009926A1 (https=)
MX (1) MX2023012030A (https=)
PE (1) PE20242078A1 (https=)
TW (1) TW202308609A (https=)
WO (1) WO2022223543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119424649A (zh) * 2024-02-29 2025-02-14 中山大学附属第一医院 假体周围感染治疗靶点及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008346A (es) * 2016-01-11 2019-07-04 Turnstone Lp Terapia de combinación de virus oncológico e inhibidor de punto de control.
IT201700041723A1 (it) 2017-04-14 2018-10-14 Italfarmaco Spa Nuovi inibitori selettivi di HDAC6

Also Published As

Publication number Publication date
BR112023021125A2 (pt) 2023-12-12
PE20242078A1 (es) 2024-10-18
EP4326259A1 (en) 2024-02-28
WO2022223543A1 (en) 2022-10-27
AU2022262199A1 (en) 2023-09-21
US20240207228A1 (en) 2024-06-27
CL2023002894A1 (es) 2024-03-15
JP2024515100A (ja) 2024-04-04
AR125356A1 (es) 2023-07-12
TW202308609A (zh) 2023-03-01
KR20230172001A (ko) 2023-12-21
IT202100009926A1 (it) 2022-10-20
IL307649A (en) 2023-12-01
CN117177745A (zh) 2023-12-05
MX2023012030A (es) 2023-10-24
CA3213275A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2021010544A (es) Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
JOP20210050A1 (ar) معدلات تعبير pnpla3
CL2019001337A1 (es) Formulaciones farmacéuticas.
AR059066A1 (es) Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX373363B (es) Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
CL2022000214A1 (es) Inhibidores de enzimas
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CO2022000270A2 (es) Inhibidores de enzimas
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
CO2023013780A2 (es) Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2013000492A1 (es) Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2022011138A (es) Efecto contra coronavirus y aplicacion de inhibidor de fosfatidilinositol 4-cinasa.
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.